• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Amnon Danzig, Business Development, M&A, Exit Management

Amnon Danzig, Business Development, M&A, Exit Management

 

Roles at LPBI Group:

  • Business Development Activities: Initiation, pursuit of leads offered, contributions to Venture’s strategic plan definition and its execution
  • Client Acquisition during the prospecting period for an acquirer for LPBI Group Intellectual Property (IP)
  • Prospecting for an acquirer for LPBI Group Intellectual Property (IP)
  • Timeline: Transaction planned for completion in late 2019-2020.
  • Finding a Buyer for the Venture’s IP for the following potential Transaction types:
  1. Outright sale of IP. A Total of 10% of Proceeds EBITA paid to Venture Founder will be allocated among all contributors to the exit activity, one day after 9, below is TRUE
  2. M&A,
  3. Licensing of variously defined “bundles of products”, See Ventures Assets, below
  4. Licensing of variously defined “bundles of services”, See Ventures Assets, below
  5. Sell of Segment(s) of the total universe of the Venture’s IP
  6. Exploration of M&As Options
  7. Complete responsibility for management of the Exit process is in the hands of a US-based executive
  8. All parties sign on the dotted line and
  9. Transaction proceeds clears.

Venture assets:

(a) The Journal, 1.5 Million eReaders, 5,450 scientific articles 

https://pharmaceuticalintelligence.com/

(b)  BioMed e-Series of e-Books – 16 volumes – The Frontier in Life Sciences and Five Specialties of Medicine

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

(c)  Archive of Top Tier Biotech Conference e-Proceedings – 60 events, Aviva Lev-Ari, PhD, RN, had attended and covered in Real Time, 2013 – Present 

https://pharmaceuticalintelligence.com/press-coverage/

 

Amnon Danzig’s Domains of Expertise: General Business Management, Strategy and Finance 

The following 8 Categories of Research on the ontology of venture’s Journal

https://pharmaceuticalintelligence.com/ represent the domains on which Mr. Danzig will be using his Author access privilege to the platform to periodically post short articles on the journal.

  1. Behavior
  2. Big Data
  3. Business Career Consideration
  4. Executive Compensation – Big Pharma
  5. Innovation
  6. Investment in Technological Breakthrough
  7. Value Based Drug Pricing
  8. Social Development

BIO

Amnon Danzig, Design and Implementation of Growth Strategies

amnon.danzig@gmail.com

+972.54.6998405

https://lnkd.in/e-zTVz4

Website: https://www.amnondanzig.com/

Linkedin: https://sg.linkedin.com/in/amnon-danzig-8949b420

 

Areas of special expertise:

  • Leading strategic processes and organizational development in global companies.
  • Leading and managing M&A initiatives.
  • Thorough understanding of business environments and organizational strategies.
  • Cooperation and agreement among members of the organization.
  • Consultation and support for the CEO.
  • Implementing structural changes:
    • Defining roles
    • Interfaces and workflows by sector
    • Measurement and control
    • Economic methods of incentive and reward.

Employment experience

2001 to present: Strategy Consultant

Worked with Stern Stewart & Co., an American consultancy firm specializing in the measurement of economic and financial performance, principles and practices of incentive and reward (EVA methodology).
Vice-President, Singapore.

  • Designed and implemented new R&D and Technology division for global agribusiness firm (late 2016-2018)

Analysis the strategic landscape, design the appropriate structure, implementation (organizational and systemwide cultural changes).

  • Designed and implemented Growth Strategies for technology firm (2015-2016)

Screened new applications for world-class technology.

  • Developed strategic new insights for Fintech firm (2016)

Added new dimensions: Corporate Finance, Geostrategic understanding, Corporate Governance.

  • Developed M&A opportunities for unique technology firm (2014)

Searched and approached global firms within the desired ecosystem

  • Turnaround process for private company, western Africa (2013)

Led reorganization effort to have the appropriate corporate governance

  • Worked with a large media company in Singapore (2009-2010)

Developed systems for economic measurement, incentive and reward based on economic measurements of value creation.

Developed a management system to motivate workers and managers to take initiative within the organization and to operate as business partners.

  • Company Headquarters, London (2008)

Development and assimilation of management systems: methods of economic measurement; incentive and reward systems, along with the appropriate adaptation of management practices.

  • Plasan Sasa, Armor and Defense Industry. Initially, as a consultant led strategic processes; subsequently, as EVP for organization, methods, and human resources (2003-2008)

Led strategy seminars.

  • Implemented insights gained from yearly strategy seminars on management procedures.
  • Led the process for building renewed managerial capabilities and foundations for human resources, in a period of growth and transition to activity on a global scale.
  • Located suitable structural and human resource solutions in response to intensive changes, and set up additional business units in Israel and abroad.
  • Organizational development, including: organizational restructuring; definition of functions; recruitment of managers and engineers to positions in the central office and branches; establishment of practices such as lines of reporting, management processes, and measurement.
  • Established a professional human resources department, including division into areas of:
    • Management and appointment of managers
    • Organization and methods
    • Recruitment
    • Professional and organizational training
    • Internal communication
    • Welfare

Additional experience:

  • Senior Lecturer at the Bar Ilan University: strategic thinking for executives and CFO courses.
  • Senior Lecturer at the Israel Management Center (IMC): senior executive courses in strategy, finances, human capital, and advanced management methodologies.
  • Lecturer for IMC directors’ course: “Selected Themes for The Strategy of the Board of Directors.”
  • Writing and publishing articles on matters of strategy for:
    • Status (an Israeli Journal of Management Thinking), and
    • For world management websites.
  • Managerial book: “From Enigma to Paradigm”, published on Amazon. Paperback and EBook.

Education

  • 2009: Course for Directors and Company Officers, Herzliya Interdisciplinary Center
  • Executive Education:
    • 2007: Merging and Acquisition, University of Chicago School of Business
    • 2007: Building and Implementing Growth Strategies, University of Chicago School of Business
    • 2006: Strategic Business Leadership: Creating and Delivering Value, University of Chicago School of Business
  • 2000: Directors’ Course, IMC
  • 1995-1997: MBA, Bradford University, Manufacturers Association, and IMC (studies in English)
  • 1986-1989: BA in Economics and Management, Rupin College

Links:

The book: “From Enigma to Paradigm”.

https://www.amazon.com/s/ref=nb_sb_ss_i_1_11?url=search-alias%3Daps&field-keywords=from+enigma+to+paradigm&sprefix=from+enigma%2Caps%2C330&crid=ETIDUFGH06ZS

Website:

https://www.amnondanzig.com/

LinkedIn:

https://www.linkedin.com/in/amnon-danzig-8949b420

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,979 other subscribers

  • Recent Posts

    • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
    • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
    • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
    • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
    • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
    • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
    • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
    • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
    • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
    • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 Rosalind Codrington, PhD
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: